Pramlintide/Metreleptin: Development discontinued

Amylin and partner Takeda discontinued development of pramlintide/metreleptin after a commercial reassessment of the obesity candidate. The companies said they would continue to evaluate other assets as potential obesity treatments under their 2009 deal. In March, Amylin and Takeda suspended a Phase II trial of pramlintide/metreleptin after 2 patients in a completed study developed antibody-related responses to metreleptin (see BioCentury, March 21). ...